Gilenya (Fingolimod) used in treatment of multiple sclerosis data to be shown by Novartis at ACTRIMS-ECTRIMS meeting in Boston , USA from September 10 to 13 , on how Novartis is redefining Multiple sclerosis treatment goals for patients
According to Novartis, new data to be presented will reinforce the clinical relevance of brain shrinkage (loss in Brain volume ) and highlight the benefit of including it as 4th key measure of Multiple sclerosis in definition of NEDA. and also other analyses will show that patients who have been treated with Gilenya (Fingolimod) were most likely to achieve NEDA based on assessment of these 4 key measures including shrinkage in brain volume than those on placebo.
Gilenya (finglolimod) local and diffuse CNS damage . It prevents cells that cause local inflammation from reaching the brain and also enters CNS(central nervous system) and reduces diffuse damage.
According to Novartis, new data to be presented will reinforce the clinical relevance of brain shrinkage (loss in Brain volume ) and highlight the benefit of including it as 4th key measure of Multiple sclerosis in definition of NEDA. and also other analyses will show that patients who have been treated with Gilenya (Fingolimod) were most likely to achieve NEDA based on assessment of these 4 key measures including shrinkage in brain volume than those on placebo.
Gilenya (finglolimod) local and diffuse CNS damage . It prevents cells that cause local inflammation from reaching the brain and also enters CNS(central nervous system) and reduces diffuse damage.